Qual é o preço para AbbVie Inc. (ABBV)

O preço para AbbVie Inc. (ABBV) é $208.57

Qual é a capitalização de mercado para AbbVie Inc. (ABBV)

A capitalização de mercado para AbbVie Inc. (ABBV) é $368.78B

AbbVie Inc. (ABBV) Ações em Circulação

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Ano	Ações em circulação	Alterar
2026 (TTM)	1.78B	-0.57%
2025	1.79B	1.23%
2024	1.77B	0.06%
2023	1.77B	-0.17%
2022	1.77B	0.06%
2021	1.77B	6.18%
2020	1.67B	12.56%
2019	1.48B	-3.89%
2018	1.54B	-3.45%
2017	1.60B	-1.60%
2016	1.62B	-0.18%
2015	1.63B	1.88%
2014	1.60B	0.38%
2013	1.59B	0.76%
2012	1.58B	-2.41%
2011	1.62B	0.00%
2010	1.62B	0.00%
2009	1.62B	0.00%

Ano

Ações em circulação

Alterar

2026 (TTM)

1.78B

-0.57%

2025

1.79B

1.23%

2024

1.77B

0.06%

2023

1.77B

-0.17%

2022

1.77B

0.06%

2021

1.77B

6.18%

2020

1.67B

12.56%

2019

1.48B

-3.89%

2018

1.54B

-3.45%

2017

1.60B

-1.60%

2016

1.62B

-0.18%

2015

1.63B

1.88%

2014

1.60B

0.38%

2013

1.59B

0.76%

2012

1.58B

-2.41%

2011

1.62B

0.00%

2010

1.62B

0.00%

2009

1.62B

0.00%

Empresa	Ações em circulação	Diferença	País
Eli Lilly LLY.US	898.00M	-49.56%	US
AstraZeneca PLC AZN.US	3.10B	74.12%	GB
Johnson & Johnson JNJ.US	2.43B	36.41%	US
Novartis AG NVS.US	1.91B	7.45%	CH
Merck & Co., Inc. MRK.US	2.49B	39.85%	US

Empresa

Ações em circulação

Diferença

País